ImageneBio Inc
IMAHealthcare|Biotechnology|US
$4.11
-0.06 (-1.44%)
DCF Value
$4.48
Tangible Book / Share
$8.79
Cash / Share
$8.42
About
ImageneBio, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for patients with immunological, autoimmune and inflammatory diseases. Its lead product candidate includes IMG-007, a non-depleting anti-OX40 monoclonal antibody that binds to OX40 receptor on activated T cells to block receptor binding to OX40 ligand which is in Phase 1b/2a clinical trial. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
Stock Price
-51.0%(1Y)
1M
-3.6%
3M
-27.9%
6M
-22.4%
YTD
-40.5%
1Y
-49.9%
3Y
-91.7%
5Y
-97.5%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$46.6M
Employees15 (+50% YoY)
CEOKristin Yarema
IPO DateFeb 27, 1998
Beta0.74
52-Week Range$3.88 – $8.84
Avg Volume12,559
ExchangeNASDAQ
Websiteinmagenebio.com
Ownership
Float63.9%
Shares Outstanding11.4M
Recent Insider Trades
Yarema KristinAWARD
Aug 14, 2026254,800 shares
Yarema KristinAWARD
Aug 14, 2026250,000 shares @ $5.84
Yarema KristinAWARD
Aug 14, 2026137,200 shares @ $5.84
Grant-Huerta YaninaAWARD
Aug 14, 202639,000 shares
Grant-Huerta YaninaAWARD
Aug 14, 202665,000 shares
Peers
Recent News
ImageneBio (NASDAQ:IMA) and Agenus (NASDAQ:AGEN) Critical Survey
Oct 6, 2026 · defenseworld.net
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 2, 2026 · globenewswire.com
ImageneBio to Participate in H.C. Wainwright 28th Annual Global Investment Conference in New York
Sep 8, 2026 · globenewswire.com
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 17, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:14 AM